Cormorant Asset Management, LLC Buys Nektar Therapeutics Inc, Sage Therapeutics Inc, Rocket Pharmaceuticals Inc, Sells Juno Therapeutics Inc, Proteostasis Therapeutics Inc, bluebird bio Inc

• New Purchases: SAGE, RCKT, TSRO, VNDA, MNLO, KDMN, SLDB, ARNA, EOLS,
• Added Positions: NKTR, MRTX, TBPH, APLS, RETA, OMER, ASND, GEMP,
• Reduced Positions: ANAB, JNCE, GTHX, MYOK, BPMC, QTNT, IFRX, AVXS, ARGX, NBIX,
• Sold Out: JUNO, PTI, BLUE, WVE, MRSN, ARDX, SYRS, OVID, ONS,

For the details of Cormorant Asset Management, LLC's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=Cormorant+Asset+Management%2C+LLC

1. Nektar Therapeutics Inc (NKTR) - 2,563,200 shares, 20.3% of the total portfolio. Shares added by 28.31%
2. Nektar Therapeutics Inc (NKTR) - 1,530,900 shares, 12.13% of the total portfolio.
3. AnaptysBio Inc (ANAB) - 1,104,022 shares, 8.57% of the total portfolio. Shares reduced by 11.78%
4. Apellis Pharmaceuticals Inc (APLS) - 4,088,229 shares, 6.74% of the total portfolio. Shares added by 8.48%
5. Mirati Therapeutics Inc (MRTX) - 1,918,350 shares, 4.39% of the total portfolio. Shares added by 55.77%

Cormorant Asset Management, LLC initiated holding in Sage Therapeutics Inc. The purchase prices were between $152.15 and $192.33, with an estimated average price of $169.69. The stock is now traded at around $151.61. The impact to a portfolio due to this purchase was 2.88%. The holding were 239,619 shares as of 2018-03-31.

Cormorant Asset Management, LLC initiated holding in Rocket Pharmaceuticals Inc. The purchase prices were between $10.44 and $19.19, with an estimated average price of $16.21. The stock is now traded at around $20.11. The impact to a portfolio due to this purchase was 2.12%. The holding were 1,519,891 shares as of 2018-03-31.

Cormorant Asset Management, LLC initiated holding in Tesaro Inc. The purchase prices were between $55.23 and $78.84, with an estimated average price of $64.33. The stock is now traded at around $43.58. The impact to a portfolio due to this purchase was 1.49%. The holding were 350,000 shares as of 2018-03-31.

Cormorant Asset Management, LLC initiated holding in Vanda Pharmaceuticals Inc. The purchase prices were between $14.05 and $20.2, with an estimated average price of $16.74. The stock is now traded at around $18.70. The impact to a portfolio due to this purchase was 1.2%. The holding were 957,821 shares as of 2018-03-31.

Cormorant Asset Management, LLC initiated holding in Menlo Therapeutics Inc. The purchase prices were between $28.51 and $37.82, with an estimated average price of $33.81. The stock is now traded at around $7.96. The impact to a portfolio due to this purchase was 0.94%. The holding were 336,714 shares as of 2018-03-31.

Cormorant Asset Management, LLC initiated holding in Kadmon Holdings Inc. The purchase prices were between $3.5 and $5.83, with an estimated average price of $4.28. The stock is now traded at around $3.96. The impact to a portfolio due to this purchase was 0.52%. The holding were 1,648,432 shares as of 2018-03-31.

Cormorant Asset Management, LLC added to a holding in Nektar Therapeutics Inc by 28.31%. The purchase prices were between $57.4 and $108.44, with an estimated average price of $85.89. The stock is now traded at around $46.25. The impact to a portfolio due to this purchase was 4.48%. The holding were 2,563,200 shares as of 2018-03-31.

Cormorant Asset Management, LLC added to a holding in Mirati Therapeutics Inc by 55.77%. The purchase prices were between $17.2 and $34.95, with an estimated average price of $27.76. The stock is now traded at around $47.20. The impact to a portfolio due to this purchase was 1.57%. The holding were 1,918,350 shares as of 2018-03-31.

Cormorant Asset Management, LLC added to a holding in Theravance Biopharma Inc by 44.44%. The purchase prices were between $23.37 and $29.71, with an estimated average price of $27.49. The stock is now traded at around $23.07. The impact to a portfolio due to this purchase was 0.72%. The holding were 1,300,000 shares as of 2018-03-31.

Cormorant Asset Management, LLC added to a holding in Reata Pharmaceuticals Inc by 125.00%. The purchase prices were between $20 and $30.19, with an estimated average price of $25.84. The stock is now traded at around $35.06. The impact to a portfolio due to this purchase was 0.38%. The holding were 450,000 shares as of 2018-03-31.

Cormorant Asset Management, LLC added to a holding in Omeros Corp by 50.18%. The purchase prices were between $9 and $20.16, with an estimated average price of $14.04. The stock is now traded at around $18.57. The impact to a portfolio due to this purchase was 0.36%. The holding were 1,314,118 shares as of 2018-03-31.

Cormorant Asset Management, LLC added to a holding in Ascendis Pharma A/S by 23.91%. The purchase prices were between $38.98 and $68.04, with an estimated average price of $56.2. The stock is now traded at around $64.34. The impact to a portfolio due to this purchase was 0.35%. The holding were 371,739 shares as of 2018-03-31.

Cormorant Asset Management, LLC sold out a holding in Juno Therapeutics Inc. The sale prices were between $45.6 and $86.96, with an estimated average price of $77.77.

Cormorant Asset Management, LLC sold out a holding in Proteostasis Therapeutics Inc. The sale prices were between $2.61 and $7.29, with an estimated average price of $4.32.

Cormorant Asset Management, LLC sold out a holding in bluebird bio Inc. The sale prices were between $163.35 and $233.05, with an estimated average price of $196.36.

Cormorant Asset Management, LLC sold out a holding in WAVE Life Sciences Ltd. The sale prices were between $32.45 and $54.7, with an estimated average price of $42.04.

Cormorant Asset Management, LLC sold out a holding in Mersana Therapeutics Inc. The sale prices were between $13.56 and $18.48, with an estimated average price of $15.79.

Cormorant Asset Management, LLC sold out a holding in Ardelyx Inc. The sale prices were between $5.05 and $7.9, with an estimated average price of $6.25.

Cormorant Asset Management, LLC reduced to a holding in Jounce Therapeutics Inc by 77.4%. The sale prices were between $12.75 and $28.4, with an estimated average price of $21.98. The stock is now traded at around $7.35. The impact to a portfolio due to this sale was -0.38%. Cormorant Asset Management, LLC still held 82,988 shares as of 2018-03-31.